Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Journal1
- Result From
- Lane Catalog1
- PubMed1
- SearchWorks (biomedical subset) 1
-
Year
- Journal Title
- Lancet1
Search Results
Sort by
- JournalDigital Access FDA Drug Device Prod Approv
- ArticleTopping DL, Dwyer T, Weller RA.Lancet. 1977 Dec 24-31;2(8052-8053):1327-8.The metabolism of very-low-density lipoproteins and chylomicrons includes the extrahepatic hydrolysis of their triglycerides by lipoprotein lipase. This results in cholesterol-rich "remnants" which are further metabolised by the liver. There is experimental evidence that in both patients with type-III hyperlipoproteinaemia and cigarette smokers hepatic-remnant metabolism may be depressed. In type-III hyperlipoproteinaemia the defect is inherited while in smokers it occurs in response to raised blood concentrations of carboxyhaemoglobin. The striking clinical similarity between type-III hyperlipoproteinaemic patients and smokers--namely, a high incidence of peripheral vascular disease--may be due to a common cause, the accumulation of cholesterol-rich remnants in the plasma.